StreetInsider.com News Articles

Form PRE 14C Sunshine Biopharma Inc. For: Oct 14

Wed, 14 Oct 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20261014/27187937.html

Form 8-K Sunshine Biopharma Inc. For: Oct 13

Wed, 14 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261014/27187135.html

Form SCHEDULE 13G Sunshine Biopharma Inc. Filed by: BJI Financial Group

Wed, 14 Oct 2026 10:42:00 -0400

si-local-file:///var/storage/secattach/20261014/27185638.html

Form SCHEDULE 13G Sunshine Biopharma Inc. Filed by: CVI Investments, Inc.

Tue, 13 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261013/27181406.html

Form 8-K Sunshine Biopharma Inc. For: Oct 08

Fri, 09 Oct 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20261009/27172375.html

Form 424B4 Sunshine Biopharma Inc.

Fri, 09 Oct 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20261009/27172367.html

Sunshine Biopharma closes $6M public offering with warrant upside

Fri, 09 Oct 2026 11:17:11 -0400

Sunshine Biopharma Inc. (NASDAQ: SBFM) has closed a public offering that generated approximately $6.0 million in gross proceeds, before placement agent fees and other expenses, according to a press release.

The offering consisted of 10,909,082 Common Units or Pre-Funded Units, priced at $0.55 per Common Unit. Each unit included one share of common stock or one Pre-Funded Warrant, along with two Series D Warrants to purchase one share of common stock at an exercise price of $0.66 per share.

The Series D Warrants are exercisable immediately and expire five years from the date of issuance. If fully exercised on a cash basis,

Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering

Fri, 09 Oct 2026 11:17:00 -0400

FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the closing of its previously announced public offering made on a reasonable best efforts basis with gross proceeds to the Company of approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.

The offering consisted of 10,909,082 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share

Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering

Fri, 09 Oct 2026 11:17:00 -0400

The offering consisted of 10,909,082 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share

Form EFFECT Sunshine Biopharma Inc.

Thu, 08 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261008/27163128.html

Form SCHEDULE 13G/A Sunshine Biopharma Inc. Filed by: Alta Partners LLC

Mon, 05 Oct 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20261005/27148789.html

Form S-1 Sunshine Biopharma Inc.

Fri, 02 Oct 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20261002/27143161.html

Form DEF 14C Sunshine Biopharma Inc. For: Sep 15

Mon, 28 Sep 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260928/27109647.html

Sunshine Biopharma launches generic Zofran in Canada

Thu, 24 Sep 2026 09:02:12 -0400

Sunshine Biopharma Inc. (NASDAQ: SBFM) has launched generic Ondansetron tablets in Canada, available in 4mg and 8mg strengths. Ondansetron is the generic equivalent of the brand-name drug Zofran and is prescribed to treat nausea and vomiting associated with cancer chemotherapy, radiation therapy, and surgery.

The company will distribute the product through its wholly owned Canadian subsidiary, Nora Pharma Inc. Ondansetron is a serotonin 5-HT3 receptor antagonist that works by blocking chemicals in the body that trigger nausea and vomiting.

According to data firm DataIntelo, the global Ondansetron market was valued at $1.82 billion in 2025 and is projected to reach $2.98 billion

Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio

Thu, 24 Sep 2026 09:00:00 -0400

FORT LAUDERDALE, FL / ACCESS Newswire / September 24, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications including drugs in the areas of oncology and antivirals, is pleased to announce that it has launched generic Ondansetron tablets of 4mg and 8mg in the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran^®.

Ondansetron is widely prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is a prescription serotonin 5-HT3 receptor antagonist. It works by

Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio

Thu, 24 Sep 2026 09:00:00 -0400

Ondansetron is widely prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is a prescription serotonin 5-HT3 receptor antagonist. It works by

Form PRE 14C Sunshine Biopharma Inc. For: Sep 15

Wed, 16 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260916/27070356.html

Form 8-K Sunshine Biopharma Inc. For: Sep 15

Wed, 16 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260916/27070285.html

Sunshine Biopharma moves coronavirus drug candidate into IND studies

Wed, 16 Sep 2026 09:01:46 -0400

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced it has advanced its lead coronavirus drug candidate into investigational new drug (IND)-enabling studies, according to a company press release.

The drug candidate, a PLpro protease inhibitor, demonstrated nanomolar potency against the viral protease and broad-spectrum activity against SARS-CoV-2 variants in vitro. In animal studies using K18-hACE2 mice infected with human SARS-CoV-2, repeated oral doses of the compound produced dose-dependent suppression of pulmonary viral replication.

The compound showed high oral bioavailability in mice, rats, and dogs, and was preferentially enriched in lung tissue in both mice and rats. The company also conducted a general mammalian toxicology

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

Wed, 16 Sep 2026 09:00:00 -0400

Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activity
Significant dose-dependent suppression of pulmonary viral replication in vivo
Strong oral bioavailability and preferential lung enrichment across multiple species

FORT LAUDERDALE, FL / ACCESS Newswire / September 16, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications including drugs in oncology and antivirals, is pleased to announce that it has advanced its lead Coronavirus drug candidate into IND-enabling studies. The Company had previously published laboratory results on its library of Anti-Coronavirus compounds in August

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

Wed, 16 Sep 2026 09:00:00 -0400

Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activity
Significant dose-dependent suppression of pulmonary viral replication in vivo
Strong oral bioavailability and preferential lung enrichment across multiple species

Form 8-K Sunshine Biopharma Inc. For: Sep 11

Fri, 11 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260911/27053555.html

Health Canada approves Sunshine Biopharma's generic Atenolol tablets

Mon, 31 Aug 2026 09:02:25 -0400

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced that Health Canada has approved its Atenolol tablets in 25mg, 50mg, and 100mg doses for the Canadian market, according to a company press release.

Atenolol is a beta-blocker and the generic equivalent of the brand-name drug Tenormin. It is indicated for managing hypertension, treating angina pectoris, and improving survival rates following a heart attack.

The company said it anticipates the product will be ready to ship to Canadian pharmacies by the end of 2026. Distribution will be handled through its wholly owned Canadian subsidiary, Nora Pharma Inc.

"With the approval of Atenolol oral tablets, Sunshine Biopharma continues

Health Canada approves Sunshine Biopharma's generic Atenolol tablets

Mon, 31 Aug 2026 09:02:25 -0400

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced that Health Canada has approved its Atenolol tablets in 25mg, 50mg, and 100mg doses for the Canadian market, according to a company press release.

"With the approval of Atenolol oral tablets, Sunshine Biopharma continues

Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions

Mon, 31 Aug 2026 09:00:00 -0400

FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®.

Atenolol belongs to a class of drugs known as beta-blockers. It works by blocking the action of certain natural chemicals in the body, such as epinephrine, on the heart and blood vessels. This effect lowers the